Category Archives: Genetics

mLOY: The genetic defect that explains why men have shorter lives than women – EL PAS USA

We have long been baffled as to why men live around five years less than women, on average. But now a new study suggests that, beyond the age of 60, the main culprit is a genetic defect: the loss of the Y chromosome, which determines sex at birth.

Its clear that men are more fragile, the question is why, explains Lars Forsberg, a researcher at Uppsala University in Sweden.

For decades it was thought that the male Y chromosomes only function was to generate sperm that determine the sex of a newborn. A boy carries one X chromosome from the mother and one Y from the father, while a girl carries two Xs, one from each parent.

In 1963, a team of scientists discovered that as men age, their blood cells lose the Y chromosome due to a copying error that happens when the mother cell divides to produce a daughter cell. In 2014, Forsberg analyzed the life expectancy of older men based on whether their blood cells had lost the Y chromosome, a mutation called mLOY. The effect recorded was mindblowing, the researcher recalls.

Men with fewer Y chromosomes had a higher risk of cancer and lived five and a half years less than those who retained this part of the genome. Three years later, Forsberg discovered that this mutation makes getting Alzheimers three times as likely. What is most worrying is the enormous prevalence of this defect. Twenty percent of men over the age of 60 have the mutation. The rate rises to 40% in those over 70 and 57% in those over 90, according to Forsbergs previous studies. It is undoubtedly the most common mutation in humans, he says.

Until now, nobody knew whether the gradual disappearance of the Y chromosome in the blood played a pivotal role in diseases associated with aging. In a study just published in the journal Science, Forsberg and scientists from Japan and the US demonstrate for the first time that this mutation increases the risk of heart problems, immune system failure and premature death.

The researchers have created the first animal model without a Y chromosome in their blood stem cells: namely, mice modified with the gene-editing tool CRISPR. The study showed that these rodents develop scarring of the heart in the form of fibrosis, one of the most common cardiovascular ailments in humans, and die earlier than normal mice. The authors then analyzed the life expectancy recorded in nearly 15,700 patients with cardiovascular disease whose data are stored in the UK public biobank. The analysis shows that loss of the Y chromosome in the blood is associated with a 30% increased risk of dying from cardiovascular disease.

This genetic factor can explain more than 75% of the difference in life expectancy between men and women over the age of 60, explains biochemist Kenneth Walsh, a researcher at the University of Virginia in the US and co-author of the study. In other words, this mutation would explain four of the five years lower life expectancy in men. Walshs estimate links to a previous study in which men with a high mLOY load live about four years less than those without it.

It is well known that men die earlier than women because they smoke and drink more and are more prone to recklessness. But, beyond the age of 60, genetics becomes the main culprit in the deterioration of their health: It seems as if men age earlier than women, Walsh points out.

The study reveals the molecular keys to the damage associated with the mLOY mutation. Within the large group of blood cells can be found the immune systems white blood cells responsible for defending the body against viruses and other pathogens. The loss of the Y chromosome triggers aberrant behavior in macrophages, a type of white blood cell, causing them to scar heart tissue, which in turn increases the risk of heart failure. Researchers have shown that the damage can be reversed if they give mice pirfenidone, a drug approved to treat humans with idiopathic pulmonary fibrosis, a condition in which the lungs become scarred and breathing becomes increasingly difficult.

There are three factors that increase the risk of Y chromosome loss. The first is the inevitable ageing process. The longer one lives, the more cell divisions occur in the body and the greater the likelihood of mutations occurring in the genome copying process. The second is smoking. Smoking causes you to lose the Y chromosome in your blood at an accelerated rate; if you stop smoking, healthy cells once again become the majority, says Walsh. But the third is also inevitable: other inherited genetic mutations can increase the gradual loss of the Y chromosome in the blood by a factor of five, explains Forsberg.

Both Forsberg and Walsh believe that this study opens up an enormous field of research. Still to be studied is whether men with this mutation also have cardiac fibrosis and whether this is behind their heart attacks and other cardiac ailments. We also need to better understand why losing the Y chromosome damages health. For now, we have shown that the Y chromosome is not just there for reproduction, but is is also important for our health, says Forsberg. The next step is to identify which genes are responsible for the phenomenon.

The loss of this chromosome has been detected in all organs and tissues of the body and at all ages, although it is more evident after 60. It is abundant in the blood because this is a tissue that produces millions of new cells every day from blood stem cells. Healthy stem cells produce healthy daughter cells and mutated ones produce daughter cells with mLOY.

A previous study showed that this mutation of the Y chromosome disrupts the function of up to 500 genes located elsewhere in the genome. It has also been shown to damage lymphocytes and natural killer cells, evident in men with prostate cancer and Alzheimers disease, respectively.

There are hardly any tests for mLOY at present. But Forsberg and his colleagues have designed a PCR test that measures the level of this mutation in the blood and could serve to determine which levels of this mutation are harmful to health. Right now, we see people in their 80s with 80% of their blood cells mutated, but we dont know what impact this has on their health, says Walsh.

Another unanswered question is why men lose the genetic mark of the male with age. The evolutionary logic, argue the authors of the paper, is that men are biologically designed to have offspring as soon as possible and to live 40 to 50 years at most. The spectacular increase in life expectancy in the last century has meant that men and women live to an advanced age 80 and 86 years in Spain, respectively which makes the effect of these mutations more evident. Another fact which possibly has some bearing on the issue: the vast majority of people who reach 100 are women.

To transform all these discoveries into treatments, we first need to better understand this phenomenon, says Forsberg. We men are not designed to live forever, but perhaps we can increase our life expectancy by a few more years.

Biochemist Jos Javier Fuster, who studies pathological mutations in blood cells at the National Center for Cardiovascular Research, stresses the importance of the work. Until now it was not clear whether the loss of Y was the cause of cancer, Alzheimers disease and heart failure, he explains. This is the first demonstration in animals that it has a causal role. The human Y chromosome is different from the mouse chromosome, so the priority now is to accumulate more data in humans. This is a great first step in understanding this new mechanism behind aging-linked diseases, he adds.

The cells of the human body group their DNA into 23 pairs of chromosomes that pair up one by one when a cell copies its genome to generate a daughter cell. The Y is the only one that does not have a symmetrical partner to pair up with: instead, it does so with an X chromosome; and the entire Y chromosome is often lost, explains Luis Alberto Prez Jurado from Pompeu Fabra University in Barcelona. For now, six genes have been identified within the Y chromosome that would be responsible for an impact on health, he says. All of them are related to the proper functioning of the immune system. In part, this would also explain the greater vulnerability of males to viral infections, including Covid-19.

Read the rest here:
mLOY: The genetic defect that explains why men have shorter lives than women - EL PAS USA

CUHK Business School Research Reveals the Genetic Makeup of a Leader – NewsPatrolling

HONG KONG SAR Media OutReach 21 July 2022 Is there such a thing as a natural-born leader? A new study sheds light on the genetic influences on leadership and found a surprising connection with bipolar disorder and alcohol consumption.

Individuals in leadership positions are more likely to have certain genes and not all of them are good. An increased tendency to drink alcohol which has been shown to cause cancer and an increased risk of bipolar disorder are among the negative health indicators associated with leaders, according to findings from a new study.Identifying these specific genes helps us understand how our biology influences occupational health and well-being, and specifically, how that plays out among people in leadership positions.Our findings provide insights into the heredity of leadership positions and also the shared genetic underpinnings between the leadership position itself and ones general health, saysLi Wendong, Associate Professor at Department of Management at The Chinese University of Hong Kong (CUHK) Business School, and a co-author of the study.Our research continues the biological story of leadership. Since the late 1980s, studies using twins have shown that differences in peoples genetic make-up account for 30 percent of differences in whether they hold leadership roles. Now we have gone a step further in and conducted genomic studies using a vast database to identify genes related to leadership, adds Prof Li, who notes that the study has implications for leaders and prospective leaders in managing their health and well-being for their long-term career development.A significant reason why our findings matter is that leaders well-being affects their behaviours, which may influence the performance and well-being of their subordinates, teams, and organisations. The implications arising from a leaders health can be vast, he says.Diving Deeper Beyond Twin StudiesThe research team, which were led by of Prof. Li, Prof. Song Zhaoli at the National University of Singapore and Prof. Fan Qiao at Duke-NUS Medical School, conducted the study using data from the U.K. Biobank, the largest public genetic and health database in the world. Researchers extracted genetic and occupational information of over 240,000 individuals of European ancestry. They also tapped on the U.K. Standard Occupation Classification and U.S. Occupational Information Network for information related to leadership roles and managing demands.Leadership has been an important and classic topic in genetic research since the early 19th century, when modern human genetics was first formed as a scientific field.Modern genetics research on leadership appeared much later using the classic twin approach. Twin studies are studies conducted on identical or fraternal twins. They aim to reveal the relative importance of environmental and genetic influences. Twin research is considered a key tool in behavioural genetics and in content fields, from biology to psychology.The new study, titledGenetics, leadership position, and well-being: An Investigation with a large-scale GWAS, furthered previous areas of inquiry by providing results from a whole-genome exploration of leadership. It unraveled genetic correlations between leadership and known measures of well-being and health. The study also considered other socioeconomic measures such as income and education so that what was revealed was a truer picture of leaders genetic profiles.Watch Out at the TopThe study brought to light possible unique genetic associations between well-being and leadership. It found that genetic influences associated with leadership position may be detrimental to well-being. This is in contrast to previous research that showed a positive correlation between leadership and general health and well-being indicators and revealed a fundamental reason why holding a leadership position is not always beneficial to ones health and well-being.After adjusting for the effects of income and education, holding leadership positions was genetically linked to a higher Body Mass Index, an increased risk for cardiovascular disease, and further reduced longevity.The high psychological demands embedded in holding leadership positions chronic stressors might play a role because they stimulate psycho-biological stress responses, including changes in fat metabolism and cardiovascular function, which are detrimental to health in the long run. says Prof. Li.In other words, leaders may be genetically pre-disposed to develop the above stress-induced diseases and conditions, but the stress involved in being a leader can trigger or exacerbate such an impact.One of the most relevant and surprising genetic markers this study found to be associated with leadership is the genetic variant linked to an increased risk of bipolar disorder and schizophrenia.While those with bipolar disorder or schizophrenia may have some advantages to become leaders, we are the first to find genetic variants linked to both leadership and bipolar disorder and schizophrenia, says Prof. Li.Bipolar disorder, formerly called manic depression, is a mental health condition that can cause mood swings of various severity, ranging from emotional highs (mania or hypomania) and lows (depression). While most people diagnosed with bipolar disorder will experience some emotional symptoms between episodes, some may not experience any.Prior research on bipolar disorder concludes that it is a mixed blessing in leaders. On the one hand, leadership studies found bipolar disorder to be linked to positive traits of high intelligence, creativity, and entrepreneurship. Other research shows it can negatively affect ones job performance.Also observed in the study is a genetic connection between leadership and an increase in alcohol consumption an unhealthy behaviour that has been shown to cause cancer.Personal Traits CountAside from strictly genetic considerations, the research team tested genetic correlations between leadership position and a set of observable personal traits that are traditionally related to leadership: intelligence, risk tolerance, and height. The results suggested that the genes that are believed to drive leadership may also be related to these traits. In finding links between the traits and underlying genes in leaders, researchers think it is possible that these genes may carry genetic influences on leadership through many of these personal traits.While genetic research into the role of leadership is in its infancy, the new study is an important step forward and is likely to shed light on the direction and scope of future studies in the field. While certain genes can play a role in whether an individual turns out to be a leader or not, they may not end up expressing themselves. At the very least, they are not a determining factor in shaping the well-being of a leader. Behaviour and lifestyle can influence the expression of genes and improve the chances of good health in leaders. And good health is always an important asset to any organisation, no matter where leadership resides, Prof. Li adds.Reference:Zhaoli Song, Wen-Dong Li, Xuye Jin, Junbiao Ying, Xin Zhang, Ying Song, Hengtong Li, and Qiao Fan,Genetics, leadership position, and well-being: An investigation with a large-scale GWAS (March 14, 2022). Available athttps://doi.org/10.1073/pnas.2114271119.This article was first published in the China Business Knowledge (CBK) website by CUHK Business School:https://bit.ly/3PsquqYHashtag: #CUHKBusinessSchool

The issuer is solely responsible for the content of this announcement.

Read the original:
CUHK Business School Research Reveals the Genetic Makeup of a Leader - NewsPatrolling

Global Immunoassay Market Strategies, Trends, Forecasts 2022-2027: The Genetic Blizzard and the Move to Point of Care Drive Dramatic Change for…

DUBLIN, July 22, 2022 /PRNewswire/ -- The "Immunoassay Market: Strategies and Trends, Forecasts by Application, Technology, Product, User and by Country, with Multiplex and Point of Care Market Analysis, Executive Guides, Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

The workhorse of the diagnostic industry is finding new legs. The pandemic has created a new demand for rapid easily available diagnostics. Immunoassay is stepping up.

Advances in genetic knowledge are creating new markets for immunoassay. Rapid diagnostics, point of care, biomarkers and consumer markets are all areas of expansion while traditional immunoassay maintains a strong position in the growing market for clinical diagnostics.

The report profiles 58 companies, large and small, working in this area. This research makes you the expert in your organization.

Key Topics Covered:

1 Market Guides1.1 Immunoassay Market - Strategic Situation Analysis & COVID Impact1.2 Guide for Executives, Marketing, Sales and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition2.1 Immunoassay Markets Definition In This Report2.1.1 Enzyme Based2.1.2 Immunofluorescence2.1.3 Chemiluminescence2.1.4 DNA/NAT2.1.5 RIA & Other2.1.6 Reagents/Kits, Analyzers, Software & Services2.1.7 Infectious Disease2.1.8 Auto-Immune2.1.9 Endocrinology2.1.10 Oncology2.1.11 Cardiology2.1.12 Other Specialty2.2 Market Definition2.2.1 Market Sizes2.2.2 Currency2.2.3 Years2.3 Methodology2.3.1 Authors2.3.2 Sources2.4 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic2.4.1 Global Healthcare Spending2.4.2 Spending on Diagnostics2.4.3 Important Role of Insurance for Diagnostics

3 Industry Overview3.1 Industry Participants3.1.1 IVD Supplier3.1.2 Independent lab specialized/esoteric3.1.3 Independent lab national/regional3.1.4 Independent lab analytical3.1.5 Public National/regional lab3.1.6 Hospital lab3.1.7 Physician lab3.1.8 Audit body3.2 The Clinical Laboratory Market Segments3.2.1 Traditional Market Segmentation3.2.2 Laboratory Focus and Segmentation3.2.3 Hospital Testing Share3.2.4 Economies of Scale3.2.5 Hospital vs. Central Lab3.2.6 Physician Office Lab's3.2.7 Physician's and POCT3.3 Immunoassay -Markets and Discussion3.3.1 Instruments - Genetics changes the picture3.3.1.1 RIA - A Technology Shows its Age3.3.1.2 Immunoassay vs. PCR vs. Sequencing - A See-Saw Battle3.3.1.3 The Smart Shrinking Instrument - Serious Implications3.3.1.4 Research Funding and Capital Expense - Instrument Pooling3.3.1.5 Multiplex vs. POC - A Tradeoff Analysis3.3.2 Reagents and Kits - Genetics changes the picture3.3.2.1 Bigger Test Menus a Boon for Kit Market3.3.2.2 Physician Office Labs - A New Frontier3.3.3 Rapid and POCT to Threaten Instrument Markets3.3.4 OTC and DTC - Huge Market Potential3.3.5 Economies of Scale. Going Away?3.3.6 Lower Barriers to Entry for Instruments/Analyzers3.3.7 Miniaturization and Technology Drive Acquisition

Story continues

4 Market Trends4.1 Factors Driving Growth4.1.1 Diagnostic Factors4.1.2 Changing Technologies Spur Early Instrument Retirement4.1.3 Consumer Channels Open Wider4.1.4 Immunity Technology Comes of Age4.2 Factors Limiting Growth4.2.1 Increased Competition Lowers Price4.2.2 Threat from PCR Based Instruments4.2.3 Lower Barriers to Entry4.2.4 Wellness has a downside4.3 Immunoassay Instrumentation4.3.1 Instrumentation Tenacity4.3.2 Declining Cost of Instruments Changes Industry Structure4.3.3 Listing of Instrument Specifications4.3.4 Immunoassay - CRISPR Diagnostics

5 Immunoassay Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 FDA Grants EUA to Xtrava Health COVID Point-of-Care Antigen Test5.3 Alamar Biosciences Raises $80M for Immuno-Sandwich Assay Platform5.4 FDA grants breakthrough device to multiplex immunoassay5.5 Quidel, Beckman Settle Cardiac Immunoassay Dispute5.6 BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership5.7 BioMerieux Gets CE Mark for Three Dengue Immunoassays5.8 COVID-19 Portfolio to Accelerate At-Home Infectious Disease Testing5.9 Roche Diagnostics Expanding Testing Portfolio in 20215.10 PerkinElmer Long-Term Outlook5.11 Quidel Updates Outlook for C19 Testing5.12 Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza5.13 Becton Dickinson and NAT Diagnostics Acquisition5.14 New test diagnoses Lyme disease within 15 minutes5.15 Multiplexed Immunoassay System Differentiates Malaria Species5.16 ERBA Mannheim Unveils Next-Generation Nexus unit5.17 Uman Diagnostics And Bio-Techne Announce Agreement For Neurofilament Light Assay5.18 Software reduces variability in ELISA biomarker tests5.19 Arrayit Corporation Allergy Testing Network Doubles

6 Profiles of Key Companies6.1 Abbott Diagnostics6.2 Abcam6.3 Arlington Scientific6.4 Arrayit Corporation6.5 Autobio Diagnostics6.6 Awareness Technology6.7 Beckman Coulter Diagnostics6.8 Becton, Dickinson and Company6.9 Biocartis6.10 Biomatik6.11 bioMerieux Diagnostics6.12 Bioneer Corporation6.13 Bio-Rad Laboratories, Inc.6.14 BioTek Instruments6.15 Boditech Med, Inc6.16 Boster Biological Technology6.17 Diamedix (Erba Diagnostics)6.18 Diasorin S.p.A.6.19 Dynex Technologies6.20 Enzo Biochem6.21 Eurofins Scientific6.22 FUJIFILM Wako Diagnostics6.23 Fujirebio6.24 Gold Standard Diagnostics6.25 Grifols6.26 Hycor Biomedical6.27 Immunodiagnostic Systems (IDS)6.28 Immunodiagnostik AG6.29 Inova Diagnostics6.30 JR Biomedical6.31 Luminex Corp6.32 Maxim Biomedical6.33 Mbio Diagnostics6.34 Meso Scale Discovery6.35 Millipore Sigma6.36 Mindray6.37 Molecular Devices6.38 MP Biomedical6.39 MyCartis6.40 Operon6.41 Ortho Clinical Diagnostics6.42 Perkin Elmer6.43 Qiagen Gmbh6.44 Quidel6.45 R&D Systems6.46 Randox Toxicology6.47 Roche Molecular Diagnostics6.48 SD Biosensor6.49 Serametrix6.50 Siemens Healthineers6.51 Sysmex6.52 Tecan6.53 Thermo Fisher Scientific Inc.6.54 TOSOH Bioscience6.55 Veredus Laboratories6.56 Vircell6.57 YD Diagnostics6.58 Zhejiang Orient Gene Biotech

7 The Global Market7.1 Global Market by Country7.2 Global Market by Application7.3 Global Market by Technology7.4 Global Market by Product7.5 Global Market by User

8 Global Market by Application8.1 Endocrinology Applications8.2 Immune Applications8.3 Oncology Applications8.4 Infectious Disease Applications8.5 Cardiology Applications8.6 Other Applications

9 Immunoassay by Technology9.1 Enzyme9.2 Fluorescence9.3 Chemiluminescence9.4 Nucleic Acid9.5 Rapid/POC9.6 Other Technology

10 Immunoassay by Product10.1 Instrument10.2 Reagents10.3 Services

11 Immunoassay by User11.1 Hospital11.2 Outpatient Lab11.3 POC/Other

12 Vision of the Future of Immunoassay

13 Appendices13.1 United States Medicare System: 2021 laboratory Fees Schedule

For more information about this report visit https://www.researchandmarkets.com/r/wnx0xr

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Cision

View original content:https://www.prnewswire.com/news-releases/global-immunoassay-market-strategies-trends-forecasts-2022-2027-the-genetic-blizzard-and-the-move-to-point-of-care-drive-dramatic-change-for-traditional-immunoassay-technology-301591725.html

SOURCE Research and Markets

View post:
Global Immunoassay Market Strategies, Trends, Forecasts 2022-2027: The Genetic Blizzard and the Move to Point of Care Drive Dramatic Change for...

Insights on the Genetic Testing Global Market to 2027 – by Type, Technology, Application and Region – Ben – Benzinga

DUBLIN, July 22, 2022 /PRNewswire/ -- The "Genetic Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global genetic testing market reached a value of US$ 14.36 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 26.39 Billion by 2027, exhibiting a CAGR of 10.67% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Genetic testing, or deoxyribonucleic acid (DNA) testing, refers to a medical technique that identifies changes in the chromosome structure or DNA sequence. It includes the collection and analysis of individual blood samples for examining the genetic condition and the chances of developing or passing various inherited disorders in laboratory settings.

Genetic testing assists in providing accurate results regarding gene mutation, eliminating the need for unnecessary checkups, and making informed decisions to manage health. At present, genetic testing is commercially available in varying types, such as carrier, diagnostic, predictive, presymptomatic and prenatal testing.

The increasing prevalence of genetic and chronic disorders across the growth represents the key factor driving the genetic testing market growth. This is further supported by the implementation of numerous favorable initiatives undertaken by the government bodies and non-governmental organizations (NGOs) for sensitizing masses regarding genetic testing. In line with this, the extensive utilization of genetic testing in pharmacogenomics, or drug-gene testing for examining the response of the body against certain medicines after its interaction with inherited genes, is contributing as another growth-inducing factor.

Additionally, the sudden outbreak of coronavirus disease (COVID-19) pandemic has led to the widespread adoption of virtual testing and the home testing kits for sample collection purposes, which, in turn, is contributing to the market growth. The tremendous technological advancements in genetic testing techniques along with the introduction of DTC-GT (Direct-to-consumer genetic testing) kits are further propelling the market growth. Other factors, such as rising investments in the research and development (R&D) activities in the field of medical science, along with the strategic collaboration amongst top players for launching advanced personalized genetic testing kits, are creating a positive outlook for the market.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 23andme Inc., Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.), Bio-RAD Laboratories Inc., Cepheid (Danaher Corporation), Eurofins Scientific, Illumina Inc., Invitae Corporation, Luminex Corporation (DiaSorin), Myriad Genetics Inc., QIAGEN, Quest Diagnostics and Thermo Fisher Scientific.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction4.1 Overview4.2 Key Industry Trends

5 Global Genetic Testing Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Forecast

6 Market Breakup by Type6.1 Predictive and Presymptomatic Testing6.1.1 Market Trends6.1.2 Market Forecast6.2 Carrier Testing6.2.1 Market Trends6.2.2 Market Forecast6.3 Prenatal and Newborn Testing6.3.1 Market Trends6.3.2 Market Forecast6.4 Diagnostic Testing6.4.1 Market Trends6.4.2 Market Forecast6.5 Pharmacogenomic Testing6.5.1 Market Trends6.5.2 Market Forecast6.6 Others6.6.1 Market Trends6.6.2 Market Forecast

7 Market Breakup by Technology7.1 Cytogenetic Testing and Chromosome Analysis7.1.1 Market Trends7.1.2 Market Forecast7.2 Biochemical Testing7.2.1 Market Trends7.2.2 Market Forecast7.3 Molecular Testing7.3.1 Market Trends7.3.2 Key Segments7.3.2.1 DNA Sequencing7.3.2.1 Others7.3.3 Market Forecast

8 Market Breakup by Application8.1 Cancer Diagnosis8.1.1 Market Trends8.1.2 Market Forecast8.2 Genetic Disease Diagnosis8.2.1 Market Trends8.2.2 Market Forecast8.3 Cardiovascular Disease Diagnosis8.3.1 Market Trends8.3.2 Market Forecast8.4 Others8.4.1 Market Trends8.4.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape14.1 Market Structure14.2 Key Players14.3 Profiles of Key Players14.3.1 23andme Inc.14.3.1.1 Company Overview14.3.1.2 Product Portfolio14.3.2 Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.)14.3.2.1 Company Overview14.3.2.2 Product Portfolio14.3.3 Bio-RAD Laboratories Inc.14.3.3.1 Company Overview14.3.3.2 Product Portfolio14.3.3.3 Financials14.3.3.4 SWOT Analysis14.3.4 Cepheid (Danaher Corporation)14.3.4.1 Company Overview14.3.4.2 Product Portfolio14.3.4.3 SWOT Analysis14.3.5 Eurofins Scientific14.3.5.1 Company Overview14.3.5.2 Product Portfolio14.3.5.3 Financials14.3.5.4 SWOT Analysis14.3.6 Illumina Inc.14.3.6.1 Company Overview14.3.6.2 Product Portfolio14.3.6.3 Financials14.3.6.4 SWOT Analysis14.3.7 Invitae Corporation14.3.7.1 Company Overview14.3.7.2 Product Portfolio14.3.7.3 Financials14.3.8 Luminex Corporation (DiaSorin)14.3.8.1 Company Overview14.3.8.2 Product Portfolio14.3.8.3 SWOT Analysis14.3.9 Myriad Genetics Inc.14.3.9.1 Company Overview14.3.9.2 Product Portfolio14.3.9.3 Financials14.3.9.4 SWOT Analysis14.3.10 QIAGEN14.3.10.1 Company Overview14.3.10.2 Product Portfolio14.3.10.3 Financials14.3.10.4 SWOT Analysis14.3.11 Quest Diagnostics14.3.11.1 Company Overview14.3.11.2 Product Portfolio14.3.11.3 Financials14.3.11.4 SWOT Analysis14.3.12 Thermo Fisher Scientific14.3.12.1 Company Overview14.3.12.2 Product Portfolio14.3.12.3 Financials14.3.12.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/te1d65

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Original post:
Insights on the Genetic Testing Global Market to 2027 - by Type, Technology, Application and Region - Ben - Benzinga

Non-random genetic alterations in the cyanobacterium Nostoc sp. exposed to space conditions | Scientific Reports – Nature.com

Schulze-Makuch, D., & Irwin, L.N. Astrobiological potential of planetary bodies within the solar system. Life in the Universe: Springer; 2018. pp. 203228.

Cockell, C. S. et al. Habitability: A review. Astrobiology 16(1), 89117 (2016).

ADS Article Google Scholar

Sancho, L. G. et al. Lichens survive in space: results from the 2005 LICHENS experiment. Astrobiology 7(3), 443454 (2007).

ADS Article Google Scholar

de La Torre, R. et al. Survival of lichens and bacteria exposed to outer space conditionsresults of the Lithopanspermia experiments. Icarus 208(2), 735748 (2010).

ADS Article Google Scholar

Rabbow, E. et al. The astrobiological mission EXPOSE-R on board of the International Space Station. Int. J. Astrobiol. 14(1), 316 (2015).

ADS Article Google Scholar

Potts, M. Nostoc 465504 (Springer, 2000).

Google Scholar

De Vera, J.-P. et al. Limits of life and the habitability of Mars: The ESA space experiment BIOMEX on the ISS. Astrobiology 19(2), 145157 (2019).

ADS Article Google Scholar

Gawad, C., Koh, W. & Quake, S. R. Single-cell genome sequencing: Current state of the science. Nat. Rev. Genet. 17(3), 175188 (2016).

CAS Article Google Scholar

Low, A. J., Koziol, A. G., Manninger, P. A., Blais, B. & Carrillo, C. D. ConFindr: Rapid detection of intraspecies and cross-species contamination in bacterial whole-genome sequence data. PeerJ 7, e6995 (2019).

Article Google Scholar

Liu, Y. & Walther-Antonio, M. Microfluidics: A new tool for microbial single cell analyses in human microbiome studies. Biomicrofluidics 11(6), 061501 (2017).

Article Google Scholar

Liu, Y. et al. The development of an effective bacterial single-cell lysis method suitable for whole genome amplification in microfluidic platforms. Micromachines. 9(8), 367 (2018).

Article Google Scholar

Liu, Y., Yao, J. & Walther-Antonio, M. Whole genome amplification of single epithelial cells dissociated from snap-frozen tissue samples in microfluidic platform. Biomicrofluidics 13(3), 034109 (2019).

Article Google Scholar

Liu, Y., Jeraldo, P., Jang, J., Eckloff, B., Jen, J., & Walther-Antonio, M. Bacterial single cell whole transcriptome amplification in microfluidic platform shows putative gene expression heterogeneity. Anal. Chem. (2019).

Liu, Y. et al. Whole genome sequencing of cyanobacterium Nostoc sp CCCryo 23106 using microfluidic single cell technology. Iscience. 25(5), 4291 (2022).

Google Scholar

https://sourceforge.net/projects/bbmap/. BBMap (2019).

Li, D., Liu, C.-M., Luo, R., Sadakane, K. & Lam, T.-W. MEGAHIT: An ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics 31(10), 16741676 (2015).

CAS Article Google Scholar

Laczny, C. C. et al. BusyBee Web: Metagenomic data analysis by bootstrapped supervised binning and annotation. Nucleic Acids Res. 45(W1), W171W179 (2017).

CAS Article Google Scholar

Parks, D. H., Imelfort, M., Skennerton, C. T., Hugenholtz, P. & Tyson, G. W. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res. 25(7), 10431055 (2015).

CAS Article Google Scholar

Parks, D. H. et al. Recovery of nearly 8000 metagenome-assembled genomes substantially expands the tree of life. Nat. Microbiol. 2(11), 1533 (2017).

CAS Article Google Scholar

Parks, D.H., Chuvochina, M., Waite, D.W., Rinke, C., Skarshewski, A., & Chaumeil, P.-A., et al. A standardized bacterial taxonomy based on genome phylogeny substantially revises the tree of life. Nat. Biotechnol. (2018).

Davis, J. J. et al. The PATRIC bioinformatics resource center: Expanding data and analysis capabilities. Nucleic Acids Res. 48(D1), D606D612 (2020).

CAS PubMed Google Scholar

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., & DePristo, M.A. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. (2010).

Ruden, D. M. et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program. SnpSift. Front. Genet. 3, 35 (2012).

PubMed Google Scholar

Yang, Z. & Bielawski, J. P. Statistical methods for detecting molecular adaptation. Trends Ecol. Evol. 15(12), 496503 (2000).

CAS Article Google Scholar

Kllberg, M. et al. Template-based protein structure modeling using the RaptorX web server. Nat. Protoc. 7(8), 1511 (2012).

Article Google Scholar

Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.8 (2015).

Pullerits, K. et al. Impact of UV irradiation at full scale on bacterial communities in drinking water. NPJ Clean Water. 3(1), 110 (2020).

Article Google Scholar

Golden, S. S. Light-responsive gene expression in cyanobacteria. J. Bacteriol. 177(7), 1651 (1995).

CAS Article Google Scholar

Dachev, T. P. et al. Overview of the ISS radiation environment observed during the ESA EXPOSE-R2 mission in 20142016. Space Weather 15(11), 14751489 (2017).

ADS Article Google Scholar

Sinha, R. P., Klisch, M., Helbling, E. W. & Hder, D.-P. Induction of mycosporine-like amino acids (MAAs) in cyanobacteria by solar ultraviolet-B radiation. J. Photochem. Photobiol. B 60(23), 129135 (2001).

CAS Article Google Scholar

Tamaru, Y., Takani, Y., Yoshida, T. & Sakamoto, T. Crucial role of extracellular polysaccharides in desiccation and freezing tolerance in the terrestrial cyanobacterium Nostoc commune. Appl. Environ. Microbiol. 71(11), 73277333 (2005).

ADS CAS Article Google Scholar

Guilhabert, M. R. & Kirkpatrick, B. C. Identification of Xylella fastidiosa antivirulence genes: hemagglutinin adhesins contribute to X fastidiosa biofilm maturation and colonization and attenuate virulence. Mol. Plant Microb. Interact. 18(8), 856868 (2005).

CAS Article Google Scholar

Nixon, R. A. & Sihag, R. K. Neurofilament phosphorylation: A new look at regulation and function. Trends Neurosci. 14(11), 501506 (1991).

CAS Article Google Scholar

Rabbow, E. et al. EXPOSE-R2: The astrobiological ESA mission on board of the International Space Station. Front. Microbiol. 8, 1533 (2017).

Article Google Scholar

Klementiev, K. E. et al. Radioprotective role of cyanobacterial phycobilisomes. Biochim. Biophys. Acta 2, 121128 (1860).

Google Scholar

Mosca, C. et al. Revival of anhydrobiotic cyanobacterium biofilms exposed to space vacuum and prolonged dryness: implications for future missions beyond low Earth orbit. Astrobiology 21(5), 541550 (2021).

ADS CAS Article Google Scholar

Kawaguchi, Y. et al. DNA damage and survival time course of deinococcal cell pellets during 3 years of exposure to outer space. Front. Microbiol. 11, 2050 (2020).

Article Google Scholar

Gladyshev, E. & Meselson, M. Extreme resistance of bdelloid rotifers to ionizing radiation. Proc. Natl. Acad. Sci. 105(13), 51395144 (2008).

ADS CAS Article Google Scholar

Zhu, Q., Niu, Y., Gundry, M. & Zong, C. Single-cell damagenome profiling unveils vulnerable genes and functional pathways in human genome toward DNA damage. Sci. Adv. 7(27), 3329 (2021).

ADS Article Google Scholar

Beaven, G. H., Holiday, E. R., Johnson, E. A., Ellis, B. & Petrow, V. The chemistry of anti-pernicious anaemia factors: Part VI: The mode of combination of component alpha in vitamin B12. J. Pharm. Pharmacol. 2(12), 944955 (1950).

CAS PubMed Google Scholar

Sinha, R., Kumar, H. D., Kumar, A. & Hder, D. Effects of UV-B irradiation on growth, survival, pigmentation and nitrogen metabolism enzymes in cyanobacteria. Acta Protozool. 34, 187 (1995).

CAS Google Scholar

Lynch, M. et al. Genetic drift, selection and the evolution of the mutation rate. Nat. Rev. Genet. 17(11), 704714 (2016).

CAS Article Google Scholar

Aleshkin, G. I., Kadzhaev, K. V. & Markov, A. P. High and low UV-dose responses in SOS-induction of the precise excision of transposons tn1, Tn5 and Tn10 in Escherichia coli. Mutat. Res. 401(12), 179191 (1998).

CAS Article Google Scholar

Zhu, Y., Neeman, T., Yap, V. B. & Huttley, G. A. Statistical methods for identifying sequence motifs affecting point mutations. Genetics 205(2), 843856 (2017).

CAS Article Google Scholar

Knight, R. D., Freeland, S. J. & Landweber, L. F. A simple model based on mutation and selection explains trends in codon and amino-acid usage and GC composition within and across genomes. Genome Biol. 2(4), 10 (2001).

Article Google Scholar

Continued here:
Non-random genetic alterations in the cyanobacterium Nostoc sp. exposed to space conditions | Scientific Reports - Nature.com

Viewpoint: In response to historical misuse of genetics to defend eugenics, some egalitarians call for defunding. Here’s why that’s not the solution -…

Its no wonder many people are wary of behavioral genetics. The field, which examines how the DNA were born with affects our behaviors, has been hijacked by eugenicists, white supremacists, and run-of-the-mill bigots as a way to justify inequality for minorities, women, poor people, and other disadvantaged groups for over a century.

But anyone interested in egalitarian goals should not shy away from the field, argues psychologist Dr. Kathryn Paige Harden. Instead, they should embrace it as a tool to inform policies that promote equality.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

Genetic research has even been used to justify eugenics: the belief that genetics indicate a natural human hierarchy that determines ones social value and standing. Eugenicists have advocated for sterilizing or otherwise attempting to eradicate individuals or entire cultural groups deemed genetically inferior or unfit due to their genes.

In response to this historic misuse, many people and organizations with egalitarian values have chosen to ignore, degrade, or ban funding for research on genetic and biological differences.

Dr. Harden takes the opposite stance. Despite or perhaps because of this historic misuse, she argues that people interested in equality cannot ignore genetic differences. To do so would allow the misinterpretation and abuse of genetic research to go unchallenged.

This is an excerpt. Read the original post here

Read more:
Viewpoint: In response to historical misuse of genetics to defend eugenics, some egalitarians call for defunding. Here's why that's not the solution -...

Genetics, wrong tests and five other reasons why some Brits dodge Covid – The Mirror

There is still a significant amount of the population who have not tested positive for covid and scientists think they have figured out why

Video Unavailable

Play now

Covid: Dr Hilary provides update as UK infection rates rise in June

As the UK makes its way through another covid surge it may seem difficult to believe that there are still people who have never caught the virus.

Thanks to a successful vaccine programme, life is back to normal and all covid restrictions have been lifted.

However, 180,000 patients have died and 22.7 million people have been affected so far, according to government data.

However, there are still people out there who have never caught the virus despite some people catching it three times and now scientists believe they have figured out why.

A number of major international studies are underway to find out whats making these people undefeated, the Daily Record reports.

Image:

In the Midlands, Dr Tara Hurst, lecturer in Biomedical Sciences at Birmingham City University, is studying this area. Dr Hurst only contracted Covid herself last autumn, but said she's aware of the 'Covid lottery'.

"There is a population who say they've never had Covid and then are those poor souls who've had it several times," she said. "It is a very complex area which is now attracting a lot of research."

Given that Covid rates are rising, it's especially important to work out what can make people immune to Covid. This is all the more crucial given that new variants will arrive on British shores which may be resistant to our vaccines.

Image:

Dr Hurst said a large number of people who proclaim to have never had coronavirus probably have had it.

"There's a high chance they had it but didn't have any symptoms," she said. "I'd say that between 45 to 90 per cent of people who think they've never had it actually have, but were asymptomatic."

She said one study had found that 45 per cent of people who tested positive actually had no symptoms. And once you've been vaccinated, there is often no way of knowing if you had ever had Covid.

There's another group of people who did have Covid but just dismissed it as a cold. This is because as the pandemic continued, the list of symptoms changed.

Dr Hurst said: "Not everyone had a cough or lost their sense of smell and taste. As the different variants arrived, so did the different symptoms and many sufferers would have just shrugged off their Covid, saying, it's just a cold."

Image:

Another factor is testing, which was crucial for gauging the official rates in the population. Some people because of their jobs (for example, teachers and healthcare workers) had to be tested regularly, others have never taken a test and if they did, only did a lateral flow one, which isn't as reliable as the PCR tests.

Dr Hurst said there's also a very special - but small - group of people who have never had Covid and haven't been vaccinated. This could be down to luck, but it's more likely there's something going on with their genetics which makes them resistant to viruses such as Covid.

"These people are very rare indeed and there's something going on with their bodies which means they can get the virus but it doesn't affect their cells, which means they don't actually develop Covid," Dr Hurst said.

A study is currently underway to delve deeper into these people's health and participants are needed (details at the bottom of this article).

Image:

As the pandemic continued, the most common way to find out if you had Covid was the Lateral Flow Test (LFT). At the height of infections, LFTs were given out free and were readily available and were easy to do.

All people had to do was put the swab up their nose and then wait a short time for the results. But LFTs weren't as reliable and accurate as the more uncomfortable PCR (polymerase chain reaction) tests, which involved the gag-inducing swabbing the back of the throat.

Some medics said LFTs were only 40 per cent accurate - which means millions of people who had a 'negative' result could in fact have been positive.

Dr Hurst said those who had not had any Covid symptoms, or never caught it, could be regarded as "super healthy". But it's more likely they have a more robust immune system

"This could be down to their genetics, but essentially they have an immune system which is super strong and fights the virus," she said.

"They will have good general health, with factors such as good levels of Vitamins C and D. Stress is also a huge factor in this, as high levels of stress can have a negative impact on the immune system."

The way you live and behave can have a big impact on whether you fall prey to Covid. Measures such as wearing a mask when out in public, avoiding large crowds, getting vaccinated and not getting too close (in proximity) to strangers are all proven to reduce your chances of getting the virus.

Just like the common cold, if you live in the countryside and don't come into close contact with people very often, then you're less likely to get it.

The answer is, nobody knows. Dr Hurst said: "I would say to those who've never had it - thank your lucky stars!"

Going forward, infections are starting to creep up again and there could be another wave in the autumn and winter and new variants are likely. Dr Hurst said: "Providing you've been vaccinated, the rest is down to common sense and being sensible."

* To find out more about taking part in the study to find out why some people have never had Covid, the details are here.

It is only open to those who've never contracted the disease and HAVEN'T been vaccinated.

Read More

Read More

Link:
Genetics, wrong tests and five other reasons why some Brits dodge Covid - The Mirror

Genetic test could tell millions of NHS patients if their hip or knee surgery will fail – iNews

Millions of people waiting for hip and knee surgery could soon be told whether their operation is likely to fail after scientists discovered a link between genetics and early failure of joint replacements.

In a world first, British researchers have found that DNA signals in saliva and blood samples are linked to an adverse reaction to the cobalt chrome materials in most joint implants.

It is thought a test to identify those patients who will have an adverse reaction to cobalt chrome will take at least two years before it can be rolled out but once in place should reduce the number of failed operations drastically.

About 15 per cent of Britons have these genetic characteristics, which make the immune system attack tissue around the material, causing pain and swelling, in a process similar to how a patient rejects an organ transplant.

Until now experts did not know what was causing the problem, which meant doctors had no way of telling if a patient would react badly to their new joint or not.

The research could lead to patients having more choice about what type of joint implant they decide on to boost their chance of success, which would transform the way orthopaedic surgery is carried out around the world.

In a trial, more than 600 patients who underwent joint-replacement surgery in the past 10 years were tested using saliva swabs and blood tests.

A computer analysed the data and revealed those patients who suffered complications carried specific genes. The team believe they can use this testing system to spot who would be at risk.

Currently, around 10 per cent of the population in the UK will have a joint surgically replaced in their lifetime, as a proven way to treat joint ailments such as arthritis. But as populations around the world grow older and heavier, this is leading to more joint replacement being performed, with some five million surgeries carried out across the world each year a number which is forecast to double over the next two decades.

The majority of patients are satisfied with the results of their surgery if joint replacements are successful they last between 15 and 25 years but a significant number of joint replacements fail early following adverse immune responses, leading to potentially dangerous and costly repeat surgery.

Patients with a genetic sensitivity to cobalt chrome usually have a second procedure within months of the first, using alternative materials.

The international study led by Newcastle University and published in Nature Communications Medicine, is the culmination of 14 years research by Dr David Langton, managing director at ExplantLab, a Newcastle-based organisation that investigates the links between genetics and the performance of medical devices which took part in the study.

Dr Langton said: Through our research we have been able to demonstrate that a significant percentage of patients carry a genotype that makes it more likely for them to have a reaction to a joint replacement made of a cobalt chrome component.

Our findings are a big step towards offering patients more choice about what type of joint implant they decide on, and helping them to make informed decisions about the risks involved.

Of the 6.4 million people currently on the waiting list for treatment on the NHS in England, more than 730,000 require orthopaedic surgery. Cobalt chrome is used in over 95 per cent of knee replacements, but alloys such as titanium and ceramic metals can be used as alternative, according to surgeons.

Tony Nargol, consultant orthopaedic surgeon at North Tees and Hartlepool NHS Foundation Trust, whose surgical team worked closely with Dr Langton, said: This exciting discovery comes as a result of the close working relationship our fantastic staff have had with Mr Langton and his team, as well as health staff from organisations across the world.

This work will help provide a practical way for health professionals to help patients in selecting the best type of implants for their individual bodies. It will mean better outcomes for our patients and could transform the quality of care we provide to our patients.

Visit link:
Genetic test could tell millions of NHS patients if their hip or knee surgery will fail - iNews

People in the News at Genomill, Oxford Nanopore, Myriad Genetics, More – GenomeWeb

Genomill: Mike Doherty

Genomill has appointedMike Doherty, the former head of product development at Foundation Medicine, to itsboard of directors. In addition to serving on the board, Doherty will also be a strategic adviser as Genomill prepares to commercialize its Geno1 technology, a pre-sequencing platform to improve cost, performance, and scalability of next-generation sequencing.

Oxford Nanopore Technologies: Duncan Tatton-Brown

Oxford Nanopore Technologies has appointed Duncan Tatton-Brown as the incoming non-executive chair. Tatton-Brown will succeed Peter Allen, who will retire from the board at the end of July 2022. Currently, Tatton-Brown is a senior adviser to Ocado Group, a UK technology company, and serves on the boards of Cazoo and Trainline. Before that, he was Ocado'sCFO from 2012 to 2020. Tatton-Brown holds a master's degree in engineering from King's College, Cambridge, UK.

Myriad Genetics: Dennis Langer

Dennis Langer, a member of Myriad Genetics' board of directors, is resigning as a director, effective June 30. After retiring from this position, Langer will provide consulting services to the company for one year.

For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.

Read more:
People in the News at Genomill, Oxford Nanopore, Myriad Genetics, More - GenomeWeb

Men’s health and infertility: Is it lifestyle or genetics? Experts answer – Hindustan Times

In the modern age, lifestyle plays a very crucial role to keep us mentally and physically healthy and when it comes to mens health, we often talk about cholesterol, diabetes, hypertension, early onset heart attack, life expectancy and so on but when it comes to reproductive health, leading to infertility or reproductive losses, males seem to be less informed. Nowadays, there is a high rise of delayed marriages and couples opting for only one or two children as infertility is now a major concern for such couples.

In about 50% of such cases, infertility is attributable to the male partner, mainly due to a failure in spermatogenesis and according to several studies, a severe decline in the sperm quality has been observed mostly contributed by the lifestyle, including smoking, drinking, long driving hours, stress and pollution. In a study done by Levine H et al., 2017, it was reported that there is a decline of 5060% in sperm counts amongst men from North America, Europe, Australia and New Zealand.

It is important to understand the various factors which impact sperm quality as well as the male fertility. In an interview with HT Lifestyle, Upasana Mukherjee, Senior Genetic Counsellor at Neuberg Center for Genomic Medicine, shared The modern man, during his reproductive period, is exposed to the negative influence of widespread lifestyle-related habits such as smoking, alcohol, recreational drugs, less physical activity etc. Effect of cigarette smoking on male fertility may result from the combined roles of elevated oxidative stress, DNA damage, and cell apoptosis, which could explain not only the reduction in semen quality but also impaired spermatogenesis, sperm maturation, and sperm function reported to be present in smokers compared to non-smokers."

She added, "Smoking is not only associated with decreased sperm quality, it has also been found to be responsible for morphological changes of sperm and also with sperm DNA damage. The high sperm DNA fragmentation rate can contribute to male infertility and has also been associated with multiple miscarriages. It is found that the higher the sperm DNA damage index, the lesser the chances of achieving an ongoing pregnancy. Sperm DNA fragmentation analysis is now offered by many labs to assess the level of damaged sperms. This in turn can help the couple to take alternative reproductive methods (ART) for a successful pregnancy. Chronic alcohol consumption has also been found to have a detrimental effect on both semen quality and the levels of male reproductive hormones.

Gaur D.S et al.,2010 conducted a study on the male partners of couples facing primary infertility and they found that teratozoospermia (abnormal sperm morphology) was present in 63% and 72% of males who drank alcohol moderately (4080g/day) and heavily (>80g/day), respectively. None of the heavy alcohol drinkers were normozoospermic and most were oligozoospermic (64%), which is suggestive of progressive testicular damage in relation to increasing daily alcohol intake. Although the effects of alcohol on male reproductive function are dependent on the intake amount, a threshold amount of alcohol beyond which the risk of male infertility increases has not yet been determined. Several recreational drugs such as marijuana, cocaine, anabolicandrogenic steroids (AAS), opiates (narcotics) and methamphetamines are examples of illicit drugs that exert a negative impact on male fertility.

Upasana Mukherjee highlighted, About 15% of males with infertility have an underlying genetic cause. The genetic landscape of male infertility is highly complex, and at least 200 genes have been implicated in spermatogenesis. Over 25% azoospermic males have genetic causes. These include mostly chromosomal abnormalities (e.g sex chromosome abnormalities, Y chromosome microdeltion) involved in severe spermatogenic impairment and autosome-linked gene variations involved in central hypogonadism, monomorphic teratozoospermia, congenital obstructive azoospermia, and familial cases of quantitative spermatogenic disturbances. Genetic testing is relevant for its diagnostic value, clinical decision making, and appropriate genetic counseling.

According to Dr Sheetal Sharda, Clinical Geneticist and Director- Genomics Development and Implementation, unlike women, men are less aware about their reproductive health and when it comes to being evaluated for infertility or pregnancy loss, often the female is evaluated first but pregnancy and a positive pregnancy outcome are both dependent on both the partners. She revealed, With better understanding and awareness, timely evaluation for a genetic diagnosis and making lifestyle modifications can improve the reproductive health of both the partners.

Here is the original post:
Men's health and infertility: Is it lifestyle or genetics? Experts answer - Hindustan Times